Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

Conditions:Blood Cancer
Therapuetic Areas:Oncology
Age Range:1 - 26
Start Date:August 4, 2017
End Date:July 2032
Contact:Colleen Annesley, MD

Use our guide to learn which trials are right for you!

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia

This study will enroll patients who have been enrolled into study PLAT-02 and meet the entry
criteria for study PLAT-03.

Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19
CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over
time. Study PLAT-03 will test whether administering T cell antigen presenting cells (T-APCs)
at intervals following treatment with CAR-T cells improves CD 19 CAR-T cell persistence and
reduces the incidence of leukemia relapse.

This pilot study seeks to examine the feasibility and safety of administering T cell antigen
presenting cells (T-APCs) designed to reactivate and numerically expand CD19-specific CAR T
cells. The underlying hypothesis to be examined is that after remission is achieved with CAR
T cell treatment, the duration, magnitude, and activation state of persisting memory CAR T
cells impact on the potential for durable leukemia eradication. This is of particular
relevance in several groups of patients we have identified: those who are predicted to lose
persistence of their CAR T cells before Day 63, or those who have definitively lost
persistence of CAR T cells prior to 6 months. By providing these patients with episodic
exposure to T-APCs capable of activating CD19-specific CAR T cells for proliferation and
redistribution to tissue beds where tumor cells of ALL seed, ideally over several months
following remission induction, it is posited that the incidence of disease relapse will be

Inclusion Criteria:

- Previous treatment under protocol PLAT-02

- Adequate performance status

- Adequate renal, liver, cardiac, and respiratory function

- Adequate absolute lymphocyte count

- HIV negative; Hepatitis B and C negative within 3 months prior to enrollment.

- Patient has sufficient stored T cell product to manufacture appropriate doses of

Exclusion Criteria:

- Evidence of active clinically significant CNS dysfunction

- Evidence of active malignancy other than CD19+ malignancy

- Evidence of active GVHD, or on immunosuppressive GVHD therapy within 4 weeks prior to
We found this trial at
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Colleen Annesley, MD
Phone: 206-987-2106
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
Seattle, WA
Click here to add this to my saved trials